Disapproval in US a Key Roadblock for Global Phenylbutazone Market

San Francisco, California, June 15, 2017: The struggle to keep pace with dynamic business trends is real for the phenylbutazone market. In the US the market has already hit a road-block due to the country-wide disapproval. Nevertheless, nonsteroidal anti-inflammatory drugs obtained from phenylbutazone are continued to be used in other parts of the world as painkillers and for treating fever. In a report, titled “Phenylbutazone Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” TMR Research presents insights into the various factors helping the market gain traction and restraints that are hampering its growth.

Intended at helping the stakeholders gain a better perspective, the report segments the global phenylbutazone market based on various parameters. Factors influencing the market’s trajectory across each of the segments are analyzed in detail. Through the forecast period, from 2017 to 2025, growth in the phenylbutazone market is expected to occur at an optimistic rate. The rising consumption of the drugs in veterinary medicines is expected to enable the market gain traction in the coming years. It is also expected to benefit from the increasing demand for NSAIDs from emerging nations in Latin America and Asia Pacific.

However, the market will continue reeling under the easy availability of substitutes and stringent restrictions imposed on the use of phenylbutazone in developed markets. Also there is likelihood for harpagophytum to replace phenylbutazone in the treatment of horse, which could foil growth opportunities for the market to an extent.

Regionally, Asia Pacific occupies the leading market share, trailed by North America and Europe. India and China have emerged as top consumers of phenylbutazone in Asia Pacific. Against this backdrop, market players with established business in developed countries are shifting toward emerging nations. Furthermore, in developing nations, the market players can benefit from cheap labor, favorable policies, and less stringent regulatory frameworks. These factors will attract an increasing number of players to the developing nations, and in turn give impetus to the overall market.

To study the competition prevailing in the global phenylbutazone market, the report profiles some of the established companies operating therein. These players are profiled based on their financial overview, product portfolio, and recent strategies. The impact of the strategies they adopt to gain better traction on the overall market is gauged as well. Some of the companies profiled in the report are Hangzhou Ruijiang Chemical Co., Ltd., Santa Cruz Biotechnology, Inc., Wuhan Yitongtai Science and Technology Co., Ltd., Baoji Guokang Bio-Technology Co., Ltd., Hangzhou Hyper Chemicals Limited, Afine Chemicals Limited, Hangzhou Hyper Chemicals Limited, been Shanghai Win-Win Biochemical Co., Ltd., Dalian Launcher Fine Chemical Co., Ltd., Shaanxi TOP Pharm Chemical Co., Ltd., Uni-med India, Croma Life Science Pvt. Ltd., Afton Pharma, Swati Chemicals, Suchem Laboratories, and Hefei TNJ Chemical Industry Co., Ltd.